Th1 pathway expression predominated at 2 weeks (Figure 6A), with more CCR5, STAT1, CD119 [IFN-γR1, linked to inflammation in MS (26)], and CCR2 (in pro-inflammatory Th1 and myeloid cells), with only partial return to baseline by 6 months after ocrelizumab infusion (Figure 6A). The gene discussed is CCR5; the disease is myeloid sarcoma.